Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial.

Arthritis Res Ther · 2015 · PMC4384235 · PMID 25876611

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Also, at week 12, the differences in mean blood flow did not reach statistical significance, indicating no significant anti-fibro-proliferative effect of ambrisentan either, in the given time frame of three months.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.